Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/10612
Title: | Targeted therapies in the treatment of renal cell carcinoma. | Austin Authors: | Pezaro, Carmel;Davis, Ian D | Affiliation: | Ludwig Institute Oncology Unit, Austin Health, Heidelberg, Victoria, Australia | Issue Date: | 2008 | Publication information: | Current Medicinal Chemistry; 15(12): 1166-74 | Abstract: | The management of renal cell carcinoma (RCC) has undergone rapid and radical evolution over the last few years. An improved understanding of the underlying biology of RCC has led to the approval of several new therapies directed against specific and relevant biological targets, so-called "targeted therapies." These highly effective treatments are now entering routine use, however many questions still remain as to how best to use these agents and integrate them into the broader therapeutic armamentarium. This review summarizes the major published clinical trials of the new agents, discusses the controversies and research questions that have arisen as a result, and considers some of the issues that remain. | Gov't Doc #: | 18473811 | URI: | https://ahro.austin.org.au/austinjspui/handle/1/10612 | Journal: | Current medicinal chemistry | URL: | https://pubmed.ncbi.nlm.nih.gov/18473811 | Type: | Journal Article | Subjects: | Angiogenesis Inhibitors.therapeutic use Animals Antineoplastic Agents.therapeutic use Carcinoma, Renal Cell.blood supply.drug therapy Clinical Trials as Topic Humans Kidney Neoplasms.blood supply.drug therapy Receptor, Epidermal Growth Factor.drug effects Regional Blood Flow.drug effects Signal Transduction.drug effects Vascular Endothelial Growth Factor A.drug effects |
Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.